Mankind Pharma Limited (MANKIND) Earnings Call Transcripts

Mankind Pharma Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Mankind Pharma Limited reported a revenue increase of 11.8% year-on-year to INR 3,443 crores, driven by strong domestic growth. The adjusted EBITDA margin improved to 27.1%, reflecting operational efficiencies and a favorable sales mix. For the fiscal year, total revenue rose 17% to INR 14,278 crores, but the profit after tax decreased by 3.4% to INR 1,938 crores, primarily due to higher finance costs and depreciation. Management provided optimistic guidance for FY '27, expecting double-digit top-line growth and improved EBITDA margins between 25.5% and 26.5%.

Reported metrics

Guidance from management

Management expects double-digit top-line growth for FY '27 and improved EBITDA margins between 25.5% and 26.5%. They are optimistic about sustaining growth in chronic and specialty therapies.

What management said

So I can say only one thing that growth would be better -- top line growth will be better than the last year, double digit. And also, we'll try to outperform IQVIA. That's the aspiration actually. And as far as the bottom line is concerned, EBITDA is concerned, that too would be better than this year '26. We can expect -- I mean, the guidance has been given 25.5% to 26.5% in the range of that.

Tushar, you cannot deny that some kind of a disruption is there as far as the raw materials are concerned, packaging metal is concerned, excipient is concerned. But whatever precautions we had to take, we have taken. And hopefully, whatever guidelines have been given, we'll try to just cover up -- we'll come up with that expectation. That's a hope actually.

What analysts pressed on

Analysts expressed concerns regarding the impact of geopolitical issues on raw material costs and potential margin pressures. Additionally, there were questions about the performance of certain key brands and the sustainability of growth in the consumer health segment.

Main topics on the call

• Revenue Growth — Mankind reported a revenue increase of 11.8% year-on-year in Q4 FY '26, reaching INR 3,443 crores. Domestic revenue, excluding Consumer Healthcare, grew by 12.9%, driven by double-digit growth in the specialty business. ...
• EBITDA Margin Improvement — The adjusted EBITDA margin for Q4 FY '26 increased to 27.1%, up from 23.1% in Q4 FY '25, attributed to a better sales mix and operational leverage. Management noted, 'This increase of 400 basis points is on account of 60...
• Profit After Tax Decline — Despite revenue growth, profit after tax for FY '26 decreased by 3.4% to INR 1,938 crores. This decline was attributed to higher finance costs and lower other income. Management acknowledged, 'We recorded higher other in...
• Guidance for FY '27 — Management provided an optimistic outlook for FY '27, expecting double-digit top-line growth and EBITDA margins between 25.5% and 26.5%. Rajeev Juneja stated, 'Top line growth will be better than last year, double digit....

Read the full Mankind Pharma Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Mankind Pharma Limited earnings call transcripts on record, spanning May 31, 2023 to July 30, 2026. Based on this history, Mankind Pharma Limited reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MANKIND

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

15

First call

May 31, 2023

Most recent

July 30, 2026

Reporting cadence

quarterly